Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Selected future therapies for Parkinson's disease
- Adenosine 2a (A2a) inhibitors
- KW-6002 restoration of balance mechanism
- Istradefylline
- Istradefylline - FDA
- Istradefylline - Japan
- Preladenant
- Preladenant - phase III
- Tozadenant
- A2a inhibitors - summary
- Levodopa - back to the future
- Levodopa carbidopa intestinal gel (LCIG)
- The pump of levadopa/cabidopa gel
- Study of levadopa-carbidopa intestinal gel
- LCIG double-blind study
- LCIG double-blind study - symptoms
- LCIG double-blind study - efficacy
- LCIG double-blind study - adverse events
- LCIG - summary
- IPX066 (Rytary)
- Study of IPX066 vs. CD/LD IR therapy
- IPX066 significantly reduced total “off” time
- IPX066 summary
- XP21279
- XP21279 phase II trial (1)
- Results of XPXP21279 phase II trial
- XP21279 phase II trial (2)
- Accordion pill CD/LD (intec pharma)
- Accordion pill CD/LD - phase II study
- Accordion pill CD/LD - PK
- Accordion pill CD/LD - efficacy - total OFF time
- Accordion pill CD/LD - efficacy - daily dose
- DM1992 – phase II (1)
- DM1992 – phase II (2)
- DM1992 – phase II (3)
- ND0612
- ND0612 – phase I study (1)
- ND0612 – phase I study (2)
- ND0612 – conclusions
- CVT-301
- CVT301 – phase I & IIa
- CVT-301 – phase IIb (CVT-301-003)
- VR040
- Safinamide
- Safinamide - animal models
- Safinamide add-on to L-dopa (SETTLE)
- Results of safinamide
- Safinamide - secondary efficacy
- Safinamide as an add-on to a DA in iPD
- Safinamide 100 mg/day
- Anti-dyskinetic agents
- mGluR5 antagonism
- AFQ056 (mavoglurant) (1)
- AFQ056 (mavoglurant) (2)
- ADX48621 (dipraglurant)
- ADX48621 - results (1)
- ADX48621 - results (2)
- Fipamezole
- Fipamezole - U.S.A vs. India
- ADS-5102
- EASED study
- EASED study - results
- EASED study - safety overview
- Summary
- Thank you
Topics Covered
- Selected Future Therapies for Motor Fluctuations and Dyskinesias
- Ankiparkinsonian agents
- A2a antagonists
- Levodopa preparations
- VR040 (inhaled apomorphine)
- Safinamide (mixed MOA : MAO-B and glu inhibition)
- Anti-dyskinetics
- AFQ056 : mGluR5 antagonist
- ADX48621 (dipraglurant) : mGluR5 negative allosteric modulator
- Fipamezole :a2 adrengergic receptor antagonist
- ADS-5102 : sustained release amantadine
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hauser, R.A. (2014, June 2). Promising medical therapies for Parkinson’s disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 12, 2024, from https://doi.org/10.69645/VQHU4022.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Robert A. Hauser has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Dr. Robert Hauser.
And I am Professor of
Neurology and Director
of the Parkinson's Disease
and Movement Disorder Center
at the University of South
Florida in Tampa, Florida.
I'll be talking about promising
medical therapies for Parkinson's
disease motor symptoms, including
motor fluctuations and dyskinesias.
0:22
I'll review antiparkinsonian
agents, including
A2a antagonists, new
levodopa preparations.
I'll mention an inhaled formulation
of apomorphine and safinamide,
a mixed MAO-B glutamate inhibitor.
I'll also talk about some
anti-dyskinetic medications
and development.
So all the medications that
I'll be talking about today
are investigational and are
not currently approved by FDA
for use in the United States or
by the regulatory authorities
in Europe.
0:56
A2a, or adenosine 2a
inhibitors, are technically
non-dopaminergic medications,
but they do interact
with the dopamine system.
In MPTP-lesioned
parkinsonian primates,
A2a inhibitors provide
motor benefit with little
or no development of dyskensia.
In addition, in MPTP-lesioned
levodopa-primed parkinsonian
animals who express dyskinesia, A2a
inhibitors improved motor function
when added to levodopa
without worsening dyskinesia.
So in these animal models
of both early and moderate
to advanced Parkinson's disease,
A2a inhibitors provide motor benefit
without causing or
worsening dyskinesia.